NEW DELHI, Aug 13- India’s Ranbaxy Laboratories’ Malaysia unit, Ranbaxy Malaysia Sdn Bhd, has been allocated a site in Kulim, Kedah, to set up its US$35 million (RM114 million) Greenfield manufacturing facility.
Rambaxy said the company signed a “letter of offer” agreement with Kulim Hi-Tech Park, a wholly-owned state agency and industrial park that houses diverse leading industries.
“In addition to serving the local market, the new facility will also export products to the Asean market, Middle East, Europe, Sri Lanka, China and other selected nations,” Ranbaxy Malaysia Managing Director T. Jeyabalan Thangarajah said in a statement.
The agreement was signed by Jeyabalan and Kulim Hi-Tech Park President Muhammad Sobri in the presence of officials from the Malaysian Investment Development Authority (MIDA) and Ranbaxy’s Chief Executive Officer and Managing Director Arun Sawhney.
Jeyabalan said the new facility, which would be built on a six hectare site, would manufacture dosage forms, including tablets and capsules, primarily in the cardiovascular, anti-diabetic, anti-infective and gastrointestinal segments.
He said Ranbaxy’s total output in Malaysia would be increased from one billion doses per annum to three billion doses per annum when the new facility was fully operational.
This will be Ranbaxy’s second manufacturing plant in Malaysia. The first in Sungai Petani was commissioned in 1987.
– BERNAMA
